Developing novel, immune-based therapies for medically unmet, life-threatening and life-limiting diseases

NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases

Apr 21, 2022

New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...

Appointment of Dr Trevor Phillips to the Board of NovaBiotics

ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director. Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech...

Publication of NovaBiotics’ peer reviewed research on cysteamine’s antiviral and anti-inflammatory mechanisms

Publication of NovaBiotics’ research on the host-mediated anti-viral (including against coronaviruses and influenza) and anti-inflammatory mechanism of action of cysteamine, the active component of its advanced clinical stage NM001 and NM002 product candidates for...

Additional International Organization for Standardisation (ISO) accreditations for NovaBiotics

NovaBiotics adds ISO 14001: 2015 and ISO 45001: 2018 accreditations to its integrated quality management system. ISO 14001: 2015 Environmental Management Systems and ISO 45001:2018 Occupational Health & Safety Systems accreditation have now been awarded to...

NovaBiotics Announces Presentations of New Data for NM002 and NP339 at the European Congress of Clinical Microbiology & Infectious Diseases

NovaBiotics to Present at the H.C. Wainwright BioConnect Conference

Aberdeen, January 4, 2022 - NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that Dr Deborah O’Neil OBE, FRSE, Chief Executive Officer of NovaBiotics,...

NovaBiotics Announces First Patient Enrolment into the Cysteamine Domain of REMAP-CAP

NovaBiotics’ NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias Aberdeen, December 8, 2021. NovaBiotics Ltd, a privately held clinical stage company developing...

NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference

by Paul McIntosh | Oct 29, 2021 | 2021, Press Releases | 0 comments Highlights new insights into cysteamine’s mechanism of action against Pseudomonas aeruginosa and Burkholderia cenocepacia, further supporting cysteamine’s potential as an antimicrobial intervention in...

NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology

Highlights potential of novel antifungal’s immune-based approach to inhibit fungal pathogens Aberdeen, October 5, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases,...

NovaBiotics publishes further data on the mechanism of action of its candidate NM001 therapy for cystic fibrosis (CF)

This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary...

NovaBiotics Highlights Advantages of Novel Immune-Based Approach to Combatting Fungal and Bacterial Infectious Diseases at Peptide Therapeutics Forum 2021

Aberdeen, August 24, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that Deborah O’Neil, Ph.D., Chief Executive Officer of NovaBiotics, delivered a...

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class therapies to address difficult-to-treat, medically unmet diseases.

The Company’s advanced portfolio of therapeutic candidates target life-threatening and life-limiting diseases in the inflammation, infection and respiratory space.

NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to initiation of phase 3 clinical trials of its portfolio of therapeutic candidates. These first in class molecules have been developed from NovaBiotics’ two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.